RVL Pharmaceuticals plc（RVLP）· 损益表

年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。

FMP · RVLP · 截至 2026-06-09

财务报表

Revenue · Gross Profit · Net Income

Breakdown	2022-12	2021-12	2020-12	2019-12	2018-12
Revenue
Revenue	$49.72M	$17.50M	$27.76M	$240.03M	$263.70M
Cost of Revenue	$9.46M	$3.62M	$3.29M	$111.63M	$140.08M
Gross Profit	$40.27M	$13.88M	$24.47M	$128.40M	$123.62M
Gross Margin %(computed)	80.98%	79.33%	88.14%	53.49%	46.88%
Operating Expenses
R&D Expenses	$3.97M	$6.93M	$13.39M	$32.32M	$43.69M
G&A Expenses	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M
Total Operating Expenses	$85.94M	$94.39M	$86.21M	$125.35M	$117.94M
Operating Income	($45.68M)	($80.51M)	($61.74M)	$3.94M	($98.54M)
Operating Margin %(computed)	-91.87%	-460.03%	-222.40%	1.64%	-37.37%
Interest Income	$2.86M	$0.00M	$0.00M	$0.00M	$0.00M
Interest Expense	$3.11M	$4.02M	$4.09M	$18.21M	$20.79M
Income Before Tax	($51.71M)	($82.53M)	($94.80M)	($298.02M)	($118.66M)
Income Tax Expense	($0.02M)	$0.32M	($5.78M)	($27.12M)	($8.98M)
Net Income	($51.69M)	($82.85M)	($89.01M)	($270.90M)	($109.68M)
Net Margin %(computed)	-103.96%	-473.40%	-320.63%	-112.86%	-41.59%
Per Share & EBITDA
EPS (Basic)	$-0.58	$-1.23	$-1.47	$-5.17	$-2.42
Wtd Avg Shares	89.80M	67.35M	60.65M	52.37M	45.28M
EBITDA	($36.19M)	($73.67M)	($69.72M)	($49.80M)	($664.39M)
EBITDA Margin %(computed)	-72.78%	-420.94%	-251.14%	-20.75%	-251.95%